HRP20192233T1 - Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba - Google Patents
Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba Download PDFInfo
- Publication number
- HRP20192233T1 HRP20192233T1 HRP20192233TT HRP20192233T HRP20192233T1 HR P20192233 T1 HRP20192233 T1 HR P20192233T1 HR P20192233T T HRP20192233T T HR P20192233TT HR P20192233 T HRP20192233 T HR P20192233T HR P20192233 T1 HRP20192233 T1 HR P20192233T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- lcdr2
- lcdr3
- hcdr2
- hcdr3
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (3)
1. Protutijelo protiv N3pGlu Aβ, koje sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje je LCDRI KSX1X2SLLYSRX3KTYLN (SEQ ID NO: 51), LCDR2 je AVSKLX4S (SEQ ID NO:52), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), te HCDRI je GYX5FTX6YYIN (SEQ ID NO: 53), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGX7TVY (SEQ ID NO: 54), gdje je XI S ili T; X2 je Q ili R, X3 je G ili S, X4 je D ili G, X5 je D ili T, X6 je R ili D, a X7 je I, T, E, ili V, naznačeno time što je namijenjeno upotrebi u sprječavanju Alzheimerove bolesti.
2. Protutijelo protiv N3pGlu Aβ, koje sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje je LCDRI KSX1X2SLLYSRX3KTYLN (SEQ ID NO: 51), LCDR2 je AVSKLX4S (SEQ ID NO:52), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), te HCDRI je GYX5FTX6YYIN (SEQ ID NO: 53), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGX7TVY (SEQ ID NO: 54), gdje je XI S ili T; X2 je Q ili R, X3 je G ili S, X4 je D ili G, X5 je D ili T, X6 je R ili D, a X7 je I, T, E, ili V, naznačeno time što je namijenjeno upotrebi u sprječavanju stanja koje se bira između kliničke ili pretkliničke Alzheimerove bolesti, prodromalne Alzheimerove bolest, te kliničke ili pretkliničke CAA.
3. Protutijelo protiv N3pGlu Aβ, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 1 ili namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje navedeni LCVR sadrži polipeptide LCDR1, LCDR2, te LCDR3, a HCVR sadrži polipeptide HCDR1, HCDR2, te HCDR3, koje se bira iz skupine koju čine:
a) LCDR1 je KSSQSLLYSRGKTYLN (SEQ ID NO: 3), LCDR2 je AVSKLDS (SEQ ID NO: 4), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), HCDR1 je GYDFTRYYIN (SEQ ID NO: 6), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGITVY (SEQ ID NO: 9);
b) LCDR1 je KSSQSLLYSRGKTYLN (SEQ ID NO: 3), LCDR2 je AVSKLDS (SEQ ID NO: 4), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), HCDR1 je GYTFTRYYIN (SEQ ID NO: 7), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGTTVY (SEQ ID NO: 10);
c) LCDR1 je KSSQSLLYSRGKTYLN (SEQ ID NO: 3), LCDR2 je AVSKLDS (SEQ ID NO: 4), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), HCDR1 je GYTFTDYYIN (SEQ ID NO: 40), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGETVY (SEQ ID NO: 41);
d) LCDR1 je KSSQSLLYSRGKTYLN (SEQ ID NO: 3), LCDR2 je AVSKLGS (SEQ ID NO: 35), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), HCDR1 je GYTFTRYYIN (SEQ ID NO: 7), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGTTVY (SEQ ID NO: 10); ili
e) LCDR1 je KSTRSLLYSRSKTYLN (SEQ ID NO: 45), LCDR2 je AVSKLDS (SEQ ID NO: 4), LCDR3 je VQGTHYPFT (SEQ ID NO: 5), HCDR1 je GYTFTDYYIN (SEQ ID NO: 40), HCDR2 je WINPGSGNTKYNEKFKG (SEQ ID NO: 8), a HCDR3 je EGVTVY (SEQ ID NO: 46).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37302610P | 2010-08-12 | 2010-08-12 | |
| EP18150424.2A EP3339323B1 (en) | 2010-08-12 | 2011-08-09 | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192233T1 true HRP20192233T1 (hr) | 2020-03-06 |
Family
ID=44543826
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160151TT HRP20160151T1 (hr) | 2010-08-12 | 2011-08-09 | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA |
| HRP20180616TT HRP20180616T1 (hr) | 2010-08-12 | 2018-04-18 | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba |
| HRP20192233TT HRP20192233T1 (hr) | 2010-08-12 | 2019-12-12 | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160151TT HRP20160151T1 (hr) | 2010-08-12 | 2011-08-09 | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA |
| HRP20180616TT HRP20180616T1 (hr) | 2010-08-12 | 2018-04-18 | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8679498B2 (hr) |
| EP (3) | EP3042917B1 (hr) |
| JP (2) | JP5980207B2 (hr) |
| KR (1) | KR101498833B1 (hr) |
| CN (2) | CN105111308B (hr) |
| AU (1) | AU2011289629B2 (hr) |
| BR (1) | BR112013004056B8 (hr) |
| CA (1) | CA2805114C (hr) |
| CL (1) | CL2013000390A1 (hr) |
| CO (1) | CO6670526A2 (hr) |
| CR (1) | CR20130016A (hr) |
| CY (2) | CY1120144T1 (hr) |
| DK (3) | DK3042917T3 (hr) |
| DO (1) | DOP2013000029A (hr) |
| EA (1) | EA023021B1 (hr) |
| EC (1) | ECSP13012436A (hr) |
| ES (3) | ES2764728T3 (hr) |
| GT (1) | GT201300036A (hr) |
| HR (3) | HRP20160151T1 (hr) |
| HU (2) | HUE037524T2 (hr) |
| IL (2) | IL224030B (hr) |
| LT (2) | LT3042917T (hr) |
| MA (1) | MA34461B1 (hr) |
| ME (3) | ME02352B (hr) |
| MX (2) | MX342782B (hr) |
| MY (2) | MY181969A (hr) |
| NO (1) | NO3042917T3 (hr) |
| NZ (2) | NZ626665A (hr) |
| PE (1) | PE20130817A1 (hr) |
| PH (1) | PH12013500277A1 (hr) |
| PL (3) | PL3042917T3 (hr) |
| PT (2) | PT3339323T (hr) |
| RS (3) | RS54685B1 (hr) |
| SG (2) | SG10201509330XA (hr) |
| SI (3) | SI3042917T1 (hr) |
| UA (1) | UA107600C2 (hr) |
| WO (1) | WO2012021469A1 (hr) |
| ZA (1) | ZA201300437B (hr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| ES2764728T3 (es) * | 2010-08-12 | 2020-06-04 | Lilly Co Eli | Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| WO2015113169A1 (en) * | 2014-02-03 | 2015-08-06 | Cnj Holdings, Inc. | Humanized beta-amyloid binding molecules and uses thereof |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| ES2989669T3 (es) * | 2014-07-10 | 2024-11-27 | Univ Zuerich | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| US20180355038A1 (en) * | 2015-09-23 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| WO2017122130A1 (en) | 2016-01-11 | 2017-07-20 | Novartis Ag | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
| JOP20170004B1 (ar) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TW201740944A (zh) * | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| TW201740954A (zh) * | 2016-03-16 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| CN109562167A (zh) * | 2016-08-09 | 2019-04-02 | 伊莱利利公司 | 联合治疗 |
| EP3500296A1 (en) | 2016-08-18 | 2019-06-26 | Eli Lilly and Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
| AR110470A1 (es) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| KR20190075068A (ko) | 2016-10-28 | 2019-06-28 | 하. 룬드벡 아크티에셀스카브 | 정신 및/또는 인지 장애의 치료를 위한 이미다조피라지논을 포함하는 병용 치료 |
| TW201827467A (zh) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| RS64289B1 (sr) | 2017-08-22 | 2023-07-31 | Biogen Ma Inc | Farmaceutske kompozicije koje sadrže anti-amiloid beta antitela |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| HUE057202T2 (hu) | 2017-12-14 | 2022-04-28 | H Lundbeck As | Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával |
| JP7194738B2 (ja) | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン |
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| JP2021516682A (ja) * | 2018-03-13 | 2021-07-08 | スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． | 破傷風神経毒素に結合する単一ドメイン抗体 |
| CN113891746B (zh) * | 2019-03-26 | 2025-05-06 | 詹森药业有限公司 | 焦谷氨酸淀粉样蛋白-β的抗体及其用途 |
| MX2022004311A (es) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| US20230250193A1 (en) * | 2020-06-17 | 2023-08-10 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| MX2023003836A (es) * | 2020-10-02 | 2023-04-14 | Lilly Co Eli | Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas. |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| CA3235104A1 (en) * | 2021-10-22 | 2023-04-27 | Kevin BIGLAN | O-glcnacase (oga) inhibitor combination therapy |
| EP4422751A1 (en) | 2021-10-29 | 2024-09-04 | Eli Lilly and Company | Compounds and methods targeting interleukin-34 |
| EP4423128A1 (en) | 2021-10-29 | 2024-09-04 | Eli Lilly and Company | Compounds and methods targeting interleukin-34 |
| WO2023076995A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| AU2022376931A1 (en) | 2021-10-29 | 2024-05-02 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| KR20240145486A (ko) | 2022-02-03 | 2024-10-07 | 일라이 릴리 앤드 캄파니 | 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화 |
| PE20250785A1 (es) | 2022-07-21 | 2025-03-14 | Lilly Co Eli | SOLUCIONES FARMACEUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTAS |
| AU2023410175A1 (en) | 2022-12-22 | 2025-07-03 | Bioarctic Ab | Antibody which binds to abetape3 |
| WO2025106313A1 (en) | 2023-11-14 | 2025-05-22 | Eli Lilly And Company | Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| SI1720909T1 (sl) * | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta protitelo |
| KR101068289B1 (ko) * | 2004-07-30 | 2011-09-28 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법 |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| AU2008242648B2 (en) * | 2007-04-18 | 2013-09-12 | Janssen Alzheimer Immunotherapy | Prevention and treatment of cerebral amyloid angiopathy |
| WO2009149487A2 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| EP2321348A2 (en) | 2008-07-09 | 2011-05-18 | University of Zürich | Method of promoting neurogenesis |
| WO2010009987A2 (en) * | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| ES2764728T3 (es) * | 2010-08-12 | 2020-06-04 | Lilly Co Eli | Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos |
-
2011
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 RS RS20160129A patent/RS54685B1/en unknown
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active Active
- 2011-08-09 PH PH1/2013/500277A patent/PH12013500277A1/en unknown
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en active Application Filing
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
-
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
-
2013
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
-
2016
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
-
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
-
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
-
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
-
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192233T1 (hr) | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba | |
| ES2656000T3 (es) | Anticuerpos frente a CGRP | |
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| NL300911I2 (nl) | sarilumab | |
| HRP20192295T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi) | |
| JP2018021031A5 (hr) | ||
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| JP2013542194A5 (hr) | ||
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ603883A (en) | Method for preparing antibodies having improved properties | |
| NZ729913A (en) | St2l antagonists and methods of use | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| JP2018515513A5 (hr) | ||
| HRP20211059T1 (hr) | Antitijela za il-17c | |
| JP2017511152A5 (hr) | ||
| JP2012527423A5 (hr) | ||
| RU2016137486A (ru) | Новое антитело против pai-1 человека | |
| ME02063B (me) | Protutijela koja se vezu na tgf-alfa i epiregulin | |
| JP2014515743A5 (hr) |